Related references
Note: Only part of the references are listed.The REPAIR Study Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension
Anton Vonk Noordegraaf et al.
JACC-CARDIOVASCULAR IMAGING (2022)
SAFETY OF MACITENTAN IN PULMONARY HYPERTENSION PATIENTS WITH ELEVATED PULMONARY CAPILLARY WEDGE PRESSURE: REAL-WORLD EVIDENCE FROM OPUS/ORPHEUS
Franck Rahaghi et al.
CHEST (2021)
Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances
Bradley A. Maron et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients
Nobuhiro Tahara et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
TREATMENT PATTERNS IN PULMONARY ARTERIAL HYPERTENSION: CHANGES IN CLINICAL PRACTICE OVER TIME USING REAL-WORLD EVIDENCE FROM THE COMBINED OPUS/ORPHEUS DATA SETS
Kelly Chin et al.
CHEST (2020)
A network meta-analysis for safety of endothelin receptor antagonists in pulmonary arterial hypertension
Yi-Jing Zhang et al.
CARDIOVASCULAR DIAGNOSIS AND THERAPY (2019)
Evaluation and classification of pulmonary arterial hypertension
Sandeep Sahay
JOURNAL OF THORACIC DISEASE (2019)
Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets
Nick Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
Alexandra K. Wong et al.
DRUG HEALTHCARE AND PATIENT SAFETY (2019)
Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
Catharina Belge et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2019)
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
Clara Hjalmarsson et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Macitentan in daily clinical practice: A single centre, 1-year experience
S. Cadenas-Menendez et al.
PULMONOLOGY (2018)
EFFICACY OF MACITENTAN IN A LARGE, REAL LIFE POPULATION OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
H. Nashat et al.
THORAX (2018)
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)
Nazzareno Galie et al.
EUROPEAN HEART JOURNAL (2016)
Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review
Maria Cristina Soares Rodrigues et al.
REVISTA LATINO-AMERICANA DE ENFERMAGEM (2016)
Pulmonary arterial hypertension: the burden of disease and impact on quality of life
Marion Delcroix et al.
EUROPEAN RESPIRATORY REVIEW (2015)
Severely reduced diffusion capacity in idiopathic pulmonary arterial. hypertension: patient characteristics and treatment responses
Pia Trip et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Tomas Pulido et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Challenges in the diagnosis and treatment of pulmonary arterial hypertension
Jean-Luc Vachiery et al.
EUROPEAN RESPIRATORY REVIEW (2012)
Early detection and management of pulmonary arterial hypertension
Marc Humbert et al.
EUROPEAN RESPIRATORY REVIEW (2012)
Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Gianluca Trifiro et al.
CURRENT DRUG METABOLISM (2011)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Marc Humbert et al.
CIRCULATION (2010)
Guidelines for the diagnosis and treatment of pulmonary hypertension
N. Galie et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Share Paper
